Patents by Inventor Allen J. Borchardt

Allen J. Borchardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
    Publication number: 20120065187
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: November 21, 2011
    Publication date: March 15, 2012
    Applicants: ALCON RESEARCH, LTD, KALYPSYS, INC.
    Inventors: Allen J. Borchardt, Clay Beauregard, Travis Cook, Robert L. Davis, Daniel A. Gamache, John M. Yanni
  • Carbazole inhibitors of histamine receptors for the treatment of disease
    Patent number: 8080566
    Abstract: The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: December 20, 2011
    Assignee: Kalypsys, Inc
    Inventors: Mehmet Kahraman, Allen J. Borchardt, Robert L. Davis, Stewart A. Noble, James W. Malecha
  • HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
    Publication number: 20100120741
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 13, 2010
    Applicants: Kalypsys, Inc., Alcon Research, Ltd
    Inventors: Allen J. Borchardt, Clay Beauregard, Travis Cook, Robert L. Davis, Daniel A. Gamache, John M. Yanni
  • AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
    Publication number: 20100063047
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 11, 2010
    Applicants: KALYPSYS, INC., ALCON RESEARCH, LTD
    Inventors: Allen J. Borchardt, Clay Beauregard, Robert L. Davis, Daniel A. Gamache, John M. Yanni
  • NOVEL INHIBITORS OF RHO KINASE
    Publication number: 20090318485
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.
    Type: Application
    Filed: July 20, 2007
    Publication date: December 24, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Allen J. Borchardt, Elisabeth M.M. Gardiner, Stewart A. Noble, Dana L. Siegel
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Patent number: 7141587
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: November 28, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Jr., Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Maria Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase
    Patent number: 7115658
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 3, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Maria Angelica Linton, John Howard Tatlock, Ru Zhou, Thomas Jay Prins, Melwyn A. Abreo
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Patent number: 7053107
    Abstract: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: May 30, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Robert Steven Kania, Cynthia L. Palmer
  • Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use
    Patent number: 6891044
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: February 15, 2003
    Date of Patent: May 10, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Jr., Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Maria Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Patent number: 6884890
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: April 26, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Jr., Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Marie Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Patent number: 6878727
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: April 12, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Michael Paul Goble
  • Pharmaceutical compositions and methods for their use
    Publication number: 20040224960
    Abstract: The present invention relates to pharmaceutical compositions and to methods for their use in decreasing cytochrome P450 (CYP450) enzyme activity. The present invention also relates to methods of increasing the bioavailability of a compound in a mammal. Additionally, the present invention relates to methods of decreasing the metabolism of certain compounds in a mammal that are metabolized by the cytochrome P450 enzyme. Furthermore, the present invention relates to pharmaceutical compositions comprising at least one compound metabolized by at least one cytochrome P450 enzyme and a cytochrome P450 enzyme-inhibiting amount of a compound of formula (I).
    Type: Application
    Filed: February 17, 2004
    Publication date: November 11, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Hui Li, Maria Angelica Linton, John Howard Tatlock
  • INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE
    Publication number: 20040220248
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Application
    Filed: February 15, 2003
    Publication date: November 4, 2004
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Marie Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Publication number: 20040192735
    Abstract: Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Application
    Filed: December 15, 2003
    Publication date: September 30, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Robert Steven Kania, Cynthia L. Palmer
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Publication number: 20040171634
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Application
    Filed: February 13, 2003
    Publication date: September 2, 2004
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Maria Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Publication number: 20040023958
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.
    Type: Application
    Filed: May 9, 2003
    Publication date: February 5, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Allen J. Borchardt, Peter Scott Dragovich, Javier Gonzalez, Tanya Michelle Jewell, Hui Li, Maria Angelica Linton, John Howard Tatlock, Ru Zhou, Thomas Jay Prins, Melwyn A. Abreo
  • Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
    Publication number: 20030195239
    Abstract: Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.
    Type: Application
    Filed: March 31, 2003
    Publication date: October 16, 2003
    Applicant: Pfizer Inc.
    Inventors: Allen J. Borchardt, Michael Paul Goble
  • Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
    Patent number: 6620828
    Abstract: Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: September 16, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Shao Song Chu, Larry Andrew Alegria, Steven Lee Bender, Suzanne Pritchett Benedict, Allen J. Borchardt, Robert Steve Kania, Mitchell David Nambu, Anna Maria Tempczyk-Russell, Sepehr Sarshar, Dilip Bhumralkar, Zhengwei Peng, Michelle Yang
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Patent number: 6534524
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: March 18, 2003
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Jr., Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Marie Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
    Patent number: 6531491
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: March 11, 2003
    Assignee: Agouron Pharamaceuticals, Inc.
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Cynthia Louise Palmer, Anna Maria Tempczyk-Russell, Michael David Varney, Michael Raymond Collins